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Sunday, February 8, 2015 125aand persistent pain. Antagonists of human TRPV1 (hTRPV1) represent a
novel therapeutic approach for the treatment of pain. Developing various
antagonists of hTRPV1, however, has been hindered by the unavailability
of a 3D structure of hTRPV1. Recently, the structure of rat TRPV1 have
been reported and it shares 85.7% sequence identity with hTRPV1. In
the present work, we constructed and reported a 3D homology tetramer
model of hTRPV1 based on the cryo-EM structures of rTRPV1. Molecular
dynamics (MD) simulations, energy minimizations, and prescreen were
applied to select and validate the best model of hTRPV1. The predicted
binding pocket of hTRPV1 consists of two adjacent monomers, which
were congruent with the experimental data and the cyro-EM structures of
rTRPV1. The detailed interactions between hTRPV1 and its antagonists
or agonists were characterized by molecular docking. Conformational
changes of hTRPV1 upon antagonist/agonist binding were also explored
by MD simulation. The different movements of compounds led to different
conformational changes of monomers in hTRPV1, indicating that TRPV1
works in a concerted way. We observed that the selective filter was open
when hTRPV1 bound with an agonist during MD simulation. For the lower
gate of hTRPV1, we observed large similarities between hTRPV1 of
agonist-bound and of antagonist bound. A five-point pharmacophore model
based on several antagonists was developed and the structural model was
used to predict new antagonists for hTRPV1. By using the 3D TRPV1
structure model above, we have performed in-silico screening and identified
candidate compounds which are currently being characterized both for
binding affinity and for functional activity on human TRPV1 (NIH
R01DA025612 and P30DA035778).
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Phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) has been recognized as an
important activator of certain transient receptor potential (TRP) channels.
More specifically, TRPV1 is a pain receptor activated by a wide range of
stimuli. However, whether or not PI(4,5)P2 is a TRPV1 agonist remains open
to debate. Utilizing a combined approach of mutagenesis and molecular
modeling, we identified a PI(4,5)P2 binding site located between the TRP
box and the S4-S5 linker. At this site PI(4,5)P2 interacts with the amino acid
residues R575 and R579 in the S4-S5 linker and with K694 in the TRP box.
We confirmed that PI(4,5)P2 behaves as a channel agonist and found that
R575, R579 and K694 mutations to alanine reduce PI(4,5)P2 binding affinity.
Additionally, in silico mutations R575A, R579A and K694A showed that the
reduction in binding affinity results from the delocalization of PI(4,5)P2 in
the binding pocket. Molecular dynamics simulations indicate that PI(4,5)P2
binding induces conformational rearrangements of the structure formed by
S6 and the TRP domain, which leads to the opening of the lower TRPV1 chan-
nel gate.
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Pain accompanies several diseases including arthritis, cancer, diabetes, and
often manifests as a disease itself. Currently, narcotic and non-narcotic drugs
that are used to treat pain have several unwanted side effects due to their
addiction, use dependence, and systemic side effects. A potential solution is
to develop a target site-specific magnetic nanoparticle based delivery of anal-
gesics. Transient Receptor Potential Vanilloid 1 (TRPV1; capsaicin receptor)
is a non-selective cation channel protein, which mediates nociceptive pain and
inflammation and is a target to develop therapeutics against chronic pain.
Capsaicin, an ingredient of hot chili peppers, desensitizes TRPV1 and inhibits
noxious pain. Here, we present the development and characterization of
capsaicin magnetic nanoparticles (CMN) for site-specific pain therapeutics.
Poly-L-lactide coglycollide (PLGA) coated CMN (PCMN) was prepared bysolvent evaporation/coprecipitation technique and determined the size of
CMN by transmission electron microscopy. Further, we determined the
drug loading, encapsulation efficiency and pharmacokinetic release profiles
of capsaicin from PCMN in vitro and examined the ability of PCMN to
activate TRPV1, by intracellular Ca2þ imaging. Thermogram of CMN and
crystalline nature of capsaicin were determined by differential scanning calo-
rimetry and x-ray diffraction techniques, respectively. Next, we analyzed the
intracellular localization of nanoparticles using fluorescein as a model drug.
Finally, we characterized the anti-nociceptive potential of PCMN by intra-
plantar injection of PCMN in mice model of inflammation and pain. Our
data demonstrate that PLGA coated CMN can be developed as a novel site-
specific analgesic. Currently, we are investigating the site-specific action of
PCMN under the influence of an external magnetic field. This novel method
of drug-delivery will revolutionize therapeutics, since it will prevent the un-
desired side effects.
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In addition to pain sensation, both thermal regulation and thermosensation are
thought to be influenced by TRPV1 channel functioning. Involvement of
TRPV1 in these latter physiological functions became clear during pharma-
ceutical development of selective TRPV1 antagonists for the treatment of
chronic painful conditions. The majority of TRPV1 antagonists that have
been progressed into clinical trials were reported to increase body temperature
(hyperthermia) in healthy humans. Currently, hyperthermia is a major concern
in pharmaceutical development of TRPV1 antagonists. We therefore sought
of an in-vitro method to identify compounds with a low hyperthermic potential
early in the drug discovery process. Using whole-cell patch clamp electro-
physiology on human TRPV1 expressing CHO cells, we performed kinetic
measurements of dissociation from the receptor of known hyperthermic
(AMG517 and ABT102) and non-hyperthermic (SB705498) TRPV1 antago-
nists. We found that AMG517 and ABT102, two hyperthermic compounds,
exhibited slow off- (dissociation) rates when channels were activated by
capsaicin. Conversely, the non-hyperthermic compound SB705498, showed
a significantly faster rate of dissociation from the receptor. Finally, we as-
sessed an in-house proprietary antagonist V116517 which demonstrated
significant separation between analgesic efficacy and hyperthermia. Once
again, this compound displayed a faster off-rate as compared to the hyperther-
mic compounds.
With these initial findings we hypothesize that the dissociation rate of an
antagonist from the TRPV1 channel is an important parameter in determining
a compound’s effect on thermal regulation and thermosensation. Antagonists
with a fast off-rate may allow endogenous ligands to interact with the TRPV1
channel and thereby fulfil its physiological role in body temperature regula-
tion while still effectively modifying pain signaling. In conclusion, our find-
ings suggest that in vitro kinetic measurements early in the drug discovery
process may be a useful means of identifying non-hyperthermic TRPV1
antagonists.
627-Pos Board B407
A Single-Residue Switch for High Temperature Dependence of Thermal
TRPV3 Channels
Beiying Liu, Feng Qin.
SUNY-Buffalo, Buffalo, NY, USA.
Thermal TRP channels, a group of ion channels from the transient receptor
potential family, play important functions in pain transduction and thermal
sensation. The channels are directly activated by temperature, with strong
temperature dependence. However, how temperature gates these channels re-
mains poorly understood. One characteristic feature of some thermal TRP
channels is hysteresis of gating. This is perhaps most prominent in vanilloid
receptor TRPV3. The channel is initially only responsive to extreme heat
with low activity, and only after repeated stimulation it becomes vigorously
responsive to warm temperatures. Importantly, the hysteresis of activation is
accompanied with a profound loss of the high temperature dependence of
the channel, suggesting that the hysteresis involves structural changes in tem-
perature sensing. Elucidation of such changes will therefore provide an oppor-
tunity to unravel the molecular mechanism underlying temperature sensing of
thermal channels. Here we examine the molecular basis underlying hysteresis
of heat activation of TRPV3. We show that the hysteresis is mediated by an N
terminal domain proximal to membranes, the same region that we have
